[{"id":"f4760edc-575b-4a03-b52a-92d92e44dfde","acronym":"","url":"https://clinicaltrials.gov/study/NCT02371135","created_at":"2021-01-18T11:17:42.064Z","updated_at":"2025-02-25T16:51:29.235Z","phase":"","brief_title":"Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes","source_id_and_acronym":"NCT02371135","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2025-02-04"},{"id":"43ad41ea-ee88-438e-ba85-a91a571ee263","acronym":"","url":"https://clinicaltrials.gov/study/NCT03996239","created_at":"2022-01-29T17:44:32.508Z","updated_at":"2024-07-02T16:34:25.688Z","phase":"","brief_title":"Researching the Effect of Aerobic Exercise on Cancer","source_id_and_acronym":"NCT03996239","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-06-14"},{"id":"ef502e78-36b6-4881-b791-586dbda2fa9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379999","created_at":"2021-01-18T21:09:15.617Z","updated_at":"2024-07-02T16:34:26.352Z","phase":"Phase 1","brief_title":"Atorvastatin ± Aspirin in Lynch Syndrome Syndrome","source_id_and_acronym":"NCT04379999","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM • CASP3","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"99825282-13d0-4537-9611-5aeeb9d9b074","acronym":"PCEDP","url":"https://clinicaltrials.gov/study/NCT02206360","created_at":"2021-01-18T10:19:50.126Z","updated_at":"2024-07-02T16:35:01.200Z","phase":"","brief_title":"Pancreatic Cancer Early Detection Program","source_id_and_acronym":"NCT02206360 - PCEDP","lead_sponsor":"White Plains Hospital","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-24"},{"id":"46d378ac-a32a-49b5-8f63-3c539b277a13","acronym":"QPCS","url":"https://clinicaltrials.gov/study/NCT04104230","created_at":"2021-01-18T20:04:23.369Z","updated_at":"2024-07-02T16:35:09.050Z","phase":"","brief_title":"Quebec Pancreas Cancer Study","source_id_and_acronym":"NCT04104230 - QPCS","lead_sponsor":"George Zogopoulos","biomarkers":" BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1","pipe":" | ","alterations":" ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 03/12/2012","start_date":" 03/12/2012","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-17"},{"id":"94e4c4f4-2bce-41ab-89c2-a3acf0b6d2b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03250078","created_at":"2021-01-18T16:03:25.897Z","updated_at":"2024-07-02T16:35:12.111Z","phase":"","brief_title":"A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals","source_id_and_acronym":"NCT03250078","lead_sponsor":"Nuvance Health","biomarkers":" BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-04-01"},{"id":"bc0ab9aa-dfd0-4ac8-8031-f30fc9f954e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411718","created_at":"2022-06-09T13:55:29.609Z","updated_at":"2024-07-02T16:35:15.093Z","phase":"Phase 2","brief_title":"A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome","source_id_and_acronym":"NCT05411718","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aspirin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-03-13"},{"id":"07c7a5d9-df0c-45c5-9b74-abae8c8d1379","acronym":"","url":"https://clinicaltrials.gov/study/NCT03751761","created_at":"2021-01-18T18:23:38.922Z","updated_at":"2024-07-02T16:35:17.456Z","phase":"Phase 1/2","brief_title":"GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study","source_id_and_acronym":"NCT03751761","lead_sponsor":"Asan Medical Center","biomarkers":" PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation","tags":["PD-L1 • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3 • PMS1 • POLD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PD-L1 amplification • POLD1 mutation • MSH3 mutation • PMS2 mutation • MLH3 mutation • PMS1 mutation • POLD2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 58","initiation":"Initiation: 06/11/2018","start_date":" 06/11/2018","primary_txt":" Primary completion: 08/30/2023","primary_completion_date":" 08/30/2023","study_txt":" Completion: 08/30/2023","study_completion_date":" 08/30/2023","last_update_posted":"2024-02-28"},{"id":"50564d19-a3cf-4bcc-8943-3dff05053f5c","acronym":"IGNITE-TX","url":"https://clinicaltrials.gov/study/NCT05677048","created_at":"2023-01-10T15:59:23.994Z","updated_at":"2024-07-02T16:35:17.318Z","phase":"","brief_title":"Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing \u0026 Treatment) Intervention","source_id_and_acronym":"NCT05677048 - IGNITE-TX","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" BRCA1 mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-02-28"},{"id":"bfb4df12-9ec3-4d7d-b560-7b4ce0e231e4","acronym":"CORAL","url":"https://clinicaltrials.gov/study/NCT05410977","created_at":"2022-06-08T11:58:19.127Z","updated_at":"2024-07-02T16:35:23.099Z","phase":"","brief_title":"Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients, CORAL Study","source_id_and_acronym":"NCT05410977 - CORAL","lead_sponsor":"Mayo Clinic","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 03/30/2022","start_date":" 03/30/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-18"},{"id":"30822141-25e9-4fd4-a1b7-75e0617cd56c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03495674","created_at":"2021-01-18T17:12:44.870Z","updated_at":"2024-07-02T16:35:24.381Z","phase":"","brief_title":"Cycling in Preventing Colorectal Cancer in Participants With Lynch Syndrome","source_id_and_acronym":"NCT03495674","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 04/04/2018","start_date":" 04/04/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 01/02/2024","study_completion_date":" 01/02/2024","last_update_posted":"2024-01-05"},{"id":"52833369-8f35-4158-93c0-4c396a7d8604","acronym":"GENERATE","url":"https://clinicaltrials.gov/study/NCT03762590","created_at":"2021-01-18T18:29:19.005Z","updated_at":"2024-07-02T16:35:25.717Z","phase":"","brief_title":"GENetic Education Risk Assessment and TEsting Study","source_id_and_acronym":"NCT03762590 - GENERATE","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 12/12/2022","primary_completion_date":" 12/12/2022","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-12-20"},{"id":"2daa2951-8e63-44d7-b2e1-6c92b1f411c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04247503","created_at":"2021-01-18T20:38:41.861Z","updated_at":"2024-07-02T16:35:41.473Z","phase":"","brief_title":"Cohort Study of Pancreatic Cancer Risk","source_id_and_acronym":"NCT04247503","lead_sponsor":"Mayo Clinic","biomarkers":" TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM","pipe":" | ","alterations":" TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation","tags":["TP53 • BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • APC • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • APC mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 12/11/2019","start_date":" 12/11/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"30d80eb1-2510-4649-9119-db4070bc1354","acronym":"CADLYNCH","url":"https://clinicaltrials.gov/study/NCT05963191","created_at":"2023-07-27T17:08:57.566Z","updated_at":"2024-07-02T16:35:41.858Z","phase":"","brief_title":"CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome","source_id_and_acronym":"NCT05963191 - CADLYNCH","lead_sponsor":"PERROD Guillaume","biomarkers":" MSH2","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 10/02/2025","study_completion_date":" 10/02/2025","last_update_posted":"2023-07-27"},{"id":"02e9230b-7c6e-47e9-b7b8-543fbe0eb06e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457101","created_at":"2022-07-13T11:56:51.208Z","updated_at":"2024-07-02T16:35:45.200Z","phase":"","brief_title":"Validation of an AI-based Biliopancreatic EUS Navigation System for Real-time Quality Improvement: A Prospective, Single-center, Randomized Controlled Trial","source_id_and_acronym":"NCT05457101","lead_sponsor":"Renmin Hospital of Wuhan University","biomarkers":" BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation","tags":["BRCA1 • BRCA2 • STK11 • MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 mutation • STK11 mutation • PALB2 mutation • MSH2 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 264","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/30/2023","study_completion_date":" 07/30/2023","last_update_posted":"2023-06-22"},{"id":"0a5b61b3-7667-454c-b61f-affb10bb9e77","acronym":"3CI Study","url":"https://clinicaltrials.gov/study/NCT04500548","created_at":"2021-01-18T21:33:32.102Z","updated_at":"2024-07-02T16:36:04.140Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study","source_id_and_acronym":"NCT04500548 - 3CI Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression","tags":["TMB • MSI • POLE • MLH1 • MSH6 • MSH2 • POLD1 • MSH3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • POLD1 mutation • PMS2 mutation • EPCAM expression • POLE mutation + POLD1 mutation • MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 06/21/2022","primary_completion_date":" 06/21/2022","study_txt":" Completion: 06/21/2022","study_completion_date":" 06/21/2022","last_update_posted":"2022-09-12"},{"id":"b9edba5c-97ab-48e7-9714-b3ab8951ab79","acronym":"MesaCAPP","url":"https://clinicaltrials.gov/study/NCT04920149","created_at":"2021-06-10T01:52:40.134Z","updated_at":"2024-07-02T16:36:14.592Z","phase":"Phase 2","brief_title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","source_id_and_acronym":"NCT04920149 - MesaCAPP","lead_sponsor":"Ann-Sofie Backman","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 03/21/2022","start_date":" 03/21/2022","primary_txt":" Primary completion: 10/15/2028","primary_completion_date":" 10/15/2028","study_txt":" Completion: 10/15/2038","study_completion_date":" 10/15/2038","last_update_posted":"2022-03-28"},{"id":"1e164106-e933-418b-8ee7-e87082235b87","acronym":"","url":"https://clinicaltrials.gov/study/NCT05131243","created_at":"2021-11-23T13:53:33.533Z","updated_at":"2024-07-02T16:36:20.346Z","phase":"","brief_title":"the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer","source_id_and_acronym":"NCT05131243","lead_sponsor":"Fujian Cancer Hospital","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation • MLH3 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2021-11-23"},{"id":"3ce0329b-2881-44da-aa28-7cd3d5304e86","acronym":"","url":"https://clinicaltrials.gov/study/NCT02048735","created_at":"2021-01-18T09:24:49.775Z","updated_at":"2024-07-02T16:37:15.587Z","phase":"Phase 1","brief_title":"Naproxen for Lynch Syndrome","source_id_and_acronym":"NCT02048735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 01/01/2021","primary_completion_date":" 01/01/2021","study_txt":"","study_completion_date":"","last_update_posted":"2017-12-12"},{"id":"7f011359-941f-464e-b15d-667c3ecb1afd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02053805","created_at":"2021-01-18T09:26:41.565Z","updated_at":"2024-07-02T16:37:17.052Z","phase":"","brief_title":"Prostate Cancer Screening Among Men With High Risk Genetic Predisposition","source_id_and_acronym":"NCT02053805","lead_sponsor":"Rabin Medical Center","biomarkers":" BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation • BRCA mutation"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2017-10-17"},{"id":"b02be5a8-9f03-4d1a-bfc1-9100d670b410","acronym":"GEOLynch","url":"https://clinicaltrials.gov/study/NCT03303833","created_at":"2021-01-18T16:19:09.339Z","updated_at":"2024-07-02T16:37:17.261Z","phase":"","brief_title":"The GEOLynch Cohort Study","source_id_and_acronym":"NCT03303833 - GEOLynch","lead_sponsor":"Wageningen University","biomarkers":" MLH1 • MSH6 • MSH2 • EPCAM","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2 • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 07/01/2006","start_date":" 07/01/2006","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2017-10-06"},{"id":"d836c584-24e4-451e-bd61-ba2b7d42a46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02864979","created_at":"2021-01-18T14:03:51.794Z","updated_at":"2024-07-02T16:37:17.661Z","phase":"Phase 2","brief_title":"Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome","source_id_and_acronym":"NCT02864979","lead_sponsor":"Rabin Medical Center","biomarkers":" MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation • PMS2 mutation","tags":["MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation • PMS2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2017-09-20"},{"id":"fccb2edd-03c9-4e74-8824-330497ea7e36","acronym":"","url":"https://clinicaltrials.gov/study/NCT01823471","created_at":"2021-01-18T08:06:07.149Z","updated_at":"2024-07-02T16:37:19.571Z","phase":"","brief_title":"I-Scan For Colon Polyp Detection In HNPCC","source_id_and_acronym":"NCT01823471","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR • MSH2 mutation","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • MSH2 mutation"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 11/01/2010","start_date":" 11/01/2010","primary_txt":" Primary completion: 06/01/2013","primary_completion_date":" 06/01/2013","study_txt":" Completion: 06/01/2013","study_completion_date":" 06/01/2013","last_update_posted":"2017-07-26"},{"id":"9b5f133c-975d-44a3-a737-4db351c53381","acronym":"","url":"https://clinicaltrials.gov/study/NCT00341575","created_at":"2021-01-18T01:10:50.227Z","updated_at":"2024-07-02T16:37:20.359Z","phase":"","brief_title":"Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer","source_id_and_acronym":"NCT00341575","lead_sponsor":"National Human Genome Research Institute (NHGRI)","biomarkers":" MSH2","pipe":" | ","alterations":" MSH2 mutation • MLH1 mutation","tags":["MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH2 mutation • MLH1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 09/28/2005","start_date":" 09/28/2005","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 08/02/2010","study_completion_date":" 08/02/2010","last_update_posted":"2017-07-02"}]